|
Demographics
| | | | | |
|
Age (years)
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
P50 (P25–P75)
|
73.00 (62–82)
|
72.00 (62–81)
|
73.00 (62–82)
| |
|
Gender
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
Male (n, %)
|
883 (54.6)
|
320 (61.7)
|
563 (51.2)
| |
| |
Female (n, %)
|
735 (45.4)
|
199 (38.3)
|
536 (48.8)
| |
|
Period
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
Wave 1 (n, %)
|
588 (36.3)
|
146 (28.1)
|
442 (40.2)
| |
| |
Between (n, %)
|
204 (12.6)
|
15 (2.9)
|
189 (17.2)
| |
| |
Wave 2 (n, %)
|
826 (51.1)
|
358 (69.0)
|
468 (42.6)
| |
|
Comorbidities
| | | | | |
|
Cardiac disease
|
Total
|
593
|
268
|
325
|
63.3%
|
| |
Yes (n, %)
|
200 (33.7)
|
72 (26.9)
|
128 (39.4)
| |
|
Immunosuppression
|
Total
|
593
|
268
|
325
|
63.3%
|
| |
Yes (n, %)
|
38 (6.4)
|
11 (4.1)
|
27 (8.3)
| |
|
Renal failure
|
Total
|
594
|
268
|
326
|
63.3%
|
| |
Yes (n, %)
|
48 (8.1)
|
17 (6.3)
|
31 (9.5)
| |
|
Symptoms
| | | | | |
|
Fever
|
Total
|
608
|
272
|
336
|
62.4%
|
| |
Yes (n, %)
|
282 (46.4)
|
169 (62.1)
|
113 (33.6)
| |
|
Dry cough
|
Total
|
607
|
272
|
335
|
62.4%
|
| |
Yes (n, %)
|
220 (36.2)
|
125 (46.0)
|
95 (28.4)
| |
|
Wet cough
|
Total
|
607
|
272
|
335
| |
| |
Yes (n, %)
|
106 (17.5)
|
45 (16.5)
|
61 (18.2)
| |
|
Dyspnea
|
Total
|
608
|
272
|
336
|
62.4%
|
| |
Yes (n, %)
|
403 (66.3)
|
192 (70.6)
|
211 (62.8)
| |
|
Diarrhea
|
Total
|
607
|
272
|
335
|
62.4%
|
| |
Yes (n, %)
|
128 (21.1)
|
69 (25.4)
|
59 (17.6)
| |
|
Biological parameters
| | | | | |
|
LDH U/L
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
P50 (P25–P75)
|
275 (219–368)
|
349 (267–457)
|
252 (205–318)
| |
|
CRP mg/L
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
P50 (P25–P75)
|
60.40 (15.1–140.9)
|
86.40 (43.6–164.2)
|
41.40 (9.50–129.9)
| |
|
Procalcitonin µg/L
|
Total
|
1615
|
588
|
202
|
0.2%
|
| |
P50 (P25–P75)
|
0.10 (0.04–0.34)
|
0.13 (0.06–0.34)
|
0.09 (0.04–0.35)
| |
|
Lymphocytes 103/mm3
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
P50 (P25–P75)
|
1.01 (0.66–1.57)
|
0.85 (0.61–1.19)
|
1.12 (0.71–1.74)
| |
|
Basophils 103/mm3
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
P50 (P25–P75)
|
0.03 (0.01–0.05)
|
0.02 (0.01–0.03)
|
0.03 (0.02–0.05)
| |
|
Eosinophils 103/mm3
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
P50 (P25–P75)
|
0.03 (0.01–0.12)
|
0.01 (0.00–0.03)
|
0.07 (0.01–0.16)
| |
|
Ferritin µg/L
|
Total
|
1614
|
519
|
1099
|
0.2%
|
| |
P50 (P25–P75)
|
332.5 (145.1–762.7)
|
702.00 (322.4–1441.4)
|
248.28 (108.8–530)
| |
|
Leukocytes 103/mm3
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
P50 (P25–P75)
|
9.40 (6.61–12.76)
|
7.02 (5.00–10.26)
|
10.40 (7.83–13.90)
| |
|
Neutrophils
103/mm3
|
Total
|
1618
|
519
|
1099
|
0%
|
| |
P50 (P25–P75)
|
7.09 (4.68–10.28)
|
5.46 (3.50–8.51)
|
8.03 (5.50–11.48)
| |
|
Chest X-ray
| | | | | |
|
Radiological anomaly
|
Total
|
1475
|
492
|
983
|
8.8%
|
|
No (n, %)
|
294 (19.9)
|
37 (7.5)
|
257 (26.1)
| |
| |
Yes (n, %)
|
1181 (80.1)
|
455 (92.5)
|
726 (73.9)
| |
|
Finding (n, %)
|
Total
|
1475
|
492
|
983
|
8.8%
|
| |
No atypical signs
|
825 (55.9)
|
106 (21.5)
|
719 (73.1)
| |
| |
Subpleural or lower lung dominant distribution
|
104 (7.1)
|
56 (11.4)
|
48 (4.9)
| |
| |
Multilobar or bilateral lesion
|
458 (31.1)
|
301 (61.2)
|
157 (16.0)
| |
| |
GGO with or without consolidation
|
88 (6.0)
|
29 (5.9)
|
59 (6.0)
| |
|
Alternative diagnosis (n, %)
|
Total
|
1618
|
519
|
1099
|
0%
|
|
More likely other diagnosis
|
309 (19.1)
|
15 (2.9)
|
294 (26.8)
| |
| |
Hard to determine
|
1055 (65.2)
|
379 (73.0)
|
676 (61.5)
| |
| |
More likely COVID-19
|
254 (15.7)
|
125 (24.1)
|
129 (11.7)
| |
|
Other finding (n, %)
|
Total
|
1475
|
492
|
983
|
8.8%
|
| |
No infiltrate
|
861 (58.4)
|
122 (24.8)
|
739 (75.2)
| |
| |
Unilateral infiltrate
|
129 (8.7)
|
48 (9.8)
|
81 (8.2)
| |
| |
Bilateral infiltrate
|
485 (32.9)
|
322 (65.4)
|
163 (16.6)
| |
